Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,520 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FIB-4 Index and Liver Stiffness Measurement are Potential Predictors of Atherosclerosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Kubotsu Y, Sakamoto Y, Tago M, Chihara A, Norita M, Inadomi C, Inoue K, Takayanagi H, Tanaka K, Isoda H, Kuwashiro T, Oeda S, Shiratori T, Anzai K, Node K, Takahashi H. Kubotsu Y, et al. Among authors: takahashi h. J Atheroscler Thromb. 2024 Sep 4. doi: 10.5551/jat.64809. Online ahead of print. J Atheroscler Thromb. 2024. PMID: 39231650 Free article.
Serum Cytokeratin 18 Fragment Is an Indicator for Treating Metabolic Dysfunction-Associated Steatotic Liver Disease.
Kawanaka M, Kamada Y, Takahashi H, Iwaki M, Nishino K, Zhao W, Seko Y, Yoneda M, Kubotsu Y, Fujii H, Sumida Y, Kawamoto H, Itoh Y, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). Kawanaka M, et al. Among authors: takahashi h. Gastro Hep Adv. 2024 Aug 14;3(8):1120-1128. doi: 10.1016/j.gastha.2024.08.008. eCollection 2024. Gastro Hep Adv. 2024. PMID: 39533978 Free PMC article.
Fast score is associated with patient-reported outcomes in patients with metabolic dysfunction-associated steatotic liver disease.
Hashida R, Kawaguchi T, Nakano D, Tsutsumi T, Kawaguchi M, Takahashi H, Tajima H, Matsuse H, Golabi P, Gerber LH, Younossi ZM, Hiraoka K. Hashida R, et al. Among authors: takahashi h. Eur J Gastroenterol Hepatol. 2025 Feb 1;37(2):190-197. doi: 10.1097/MEG.0000000000002895. Epub 2024 Dec 2. Eur J Gastroenterol Hepatol. 2025. PMID: 39621860
Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis.
Kumazaki S, Hikita H, Tahata Y, Sung JH, Fukumoto K, Myojin Y, Sakane S, Murai K, Sasaki Y, Shirai K, Saito Y, Kodama T, Kakita N, Takahashi H, Toyoda H, Suda G, Morii E, Kojima T, Ebihara T, Shimizu K, Sasaki Y, Tatsumi T, Takehara T. Kumazaki S, et al. Among authors: takahashi h. Aliment Pharmacol Ther. 2024 Aug;60(3):327-339. doi: 10.1111/apt.18063. Epub 2024 Jun 3. Aliment Pharmacol Ther. 2024. PMID: 38828944
14,520 results
You have reached the last available page of results. Please see the User Guide for more information.